Literature DB >> 20718606

Clinical risk factors for invasive aspergillosis.

John W Baddley1.   

Abstract

Despite improvements in the antifungal armamentarium and diagnostic modalities, invasive aspergillosis (IA) remains an important cause of morbidity and mortality in immunocompromised patients. There is an emergence of non-traditional groups at risk for IA, including intensive care unit (ICU) patients, post-operative patients, those with chronic pulmonary diseases, patients with AIDS and patients on immunomodulating drugs (TNF-α inhibitors). Identification of clinical risk factors for IA may help in determining which patients require risk modification and other prevention measures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718606     DOI: 10.3109/13693786.2010.505204

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  54 in total

1.  Aspergillus fumigatus Cell Wall Promotes Apical Airway Epithelial Recruitment of Human Neutrophils.

Authors:  Michael B Feldman; Richard A Dutko; Michael A Wood; Rebecca A Ward; Hui Min Leung; Ryan F Snow; Denis J De La Flor; Lael M Yonker; Jennifer L Reedy; Guillermo J Tearney; Hongmei Mou; Bryan P Hurley; Jatin M Vyas
Journal:  Infect Immun       Date:  2020-01-22       Impact factor: 3.441

2.  Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis.

Authors:  Emrah Şeyhoğlu; Abdülsamet Erden; Levent Kılıç; Ömer Karadağ; Sevtap Arıkan Akdağlı; Ali Akdoğan; Umut Kalyoncu
Journal:  Eur J Rheumatol       Date:  2018-03

3.  A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS.

Authors:  R J van de Peppel; P A von dem Borne; S le Cessie; M G J de Boer
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

4.  Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis.

Authors:  Gaston Burghi; Virginie Lemiale; Amélie Seguin; Jérôme Lambert; Claire Lacroix; Emmanuel Canet; Anne-Sophie Moreau; Patricia Ribaud; David Schnell; Eric Mariotte; Benoît Schlemmer; Elie Azoulay
Journal:  Intensive Care Med       Date:  2011-08-25       Impact factor: 17.440

5.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

6.  Predicting Invasive Aspergillosis in Hematology Patients by Combining Clinical and Genetic Risk Factors with Early Diagnostic Biomarkers.

Authors:  P Lewis White; Christian Parr; Rosemary A Barnes
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

7.  Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

8.  Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.

Authors:  Mark F Mabanglo; Michael A Hast; Nathan B Lubock; Homme W Hellinga; Lorena S Beese
Journal:  Protein Sci       Date:  2014-01-31       Impact factor: 6.725

9.  Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis.

Authors:  M Jurado; J Sainz; C B Lupiañez; M Martínez-Bueno; J M Sánchez-Maldonado; J Badiola; C Cunha; J Springer; M Lackner; J Segura-Catena; L M Canet; L Alcazar-Fuoli; M A López-Nevot; L Fianchi; J M Aguado; L Pagano; E López-Fernández; M Alarcón-Riquelme; L Potenza; S M Gonçalves; M Luppi; L Moratalla; C Solano; A Sampedro; P González-Sierra; M Cuenca-Estrella; K Lagrou; J A Maertens; C Lass-Flörl; H Einsele; L Vazquez; J Loeffler; R Ríos-Tamayo; A Carvalho
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 10.  Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools.

Authors:  Stefan Zimmerli; Ralf Bialek; Igor W Blau; Andreas Christe; Cornelia Lass-Flörl; Elisabeth Presterl
Journal:  Mycopathologia       Date:  2016-04-26       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.